Skip to content Skip to footer

Milestone in the fight against the trigger of a form of leukaemia in cooperation between TU Dresden, PROVIREX and the Friedrich Alexander University Erlangen-Nuremberg (FAU)

Triggering aggressive forms of leukaemia or an incurable spinal cord disease that leads to paralysis. HTLV-1 virus is the often ignored but no less insidious sibling of the AIDS pathogen HIV, also belonging to the retroviruses. A group of researchers from the TU Dresden, the company PROVIREX Genome Editing Therapies and the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have now provided initial proof of concept for a possible therapeutic approach.

Read here the original Press Release.

Genome Editing Therapies GmbH

Luruper Hauptstraße 1
22547 Hamburg


Copyright © PROVIREX Genome Editing Therapies GmbH 2023